Sanofi will create a separate company for the production of AFS

By 2022, the French pharmaceutical company Sanofi intends to allocate its business of manufacturing active pharmaceutical ingredients (AFS) as a separate business. Currently being prepared for listing on the stock exchange, reports Reuters.

In December 2019 Executive Director of Sanofi Paul Hudson presented a plan to increase company revenues by 2022. Among other things it was proposed to complete the development of drugs for the treatment of diabetes and cardiovascular disease, reduce costs, and to allocate the production of AFS as a separate business.

According to forecasts, the new company will amount to 1-2 billion euros. The business will include the production site of Sanofi in France, Italy, Germany, UK and Hungary.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]